Atea Pharmaceuticals Inc (AVIR) — Cash Flow-to-Debt Ratio
Atea Pharmaceuticals Inc (AVIR) has a Cash Flow-to-Debt Ratio of -1.39x as of March 2026, meaning its operating cash flow of $-46.39 Million could theoretically repay -1% of its total liabilities ($33.37 Million) in one year. Check total reinvestment intensity of Atea Pharmaceuticals Inc to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Atea Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2018–2025)
Historical debt coverage capacity for Atea Pharmaceuticals Inc across 8 annual periods. Also explore Atea Pharmaceuticals Inc assets under control for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Atea Pharmaceuticals Inc (2018–2025)
Year-by-year debt coverage analysis for Atea Pharmaceuticals Inc. For market capitalisation and broader financial context, see Atea Pharmaceuticals Inc (AVIR) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.32x | $-132.03 Million | $39.78 Million | ▲ +36.8% |
| 2024 | -5.25x | $-135.50 Million | $25.80 Million | ▼ -144.6% |
| 2023 | -2.15x | $-85.39 Million | $39.78 Million | ▲ +53.6% |
| 2022 | -4.63x | $-120.98 Million | $26.14 Million | ▼ -234.2% |
| 2021 | -1.39x | $-87.00 Million | $62.81 Million | ▼ -247.4% |
| 2020 | 0.94x | $296.73 Million | $315.83 Million | ▲ +625.3% |
| 2019 | -0.18x | $-12.81 Million | $71.64 Million | ▼ -60.6% |
| 2018 | -0.11x | $-7.91 Million | $71.02 Million | — |